



APG report

Date: Wednesday 07 June 2023 **Quorate:** Yes

The items in this report are supported by the area prescribing group and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

New medicines NICE TAs

Drug and indication	RAG	Notes	ICB approval
CASIRIVIMAB plus IMDEVIMAB solution for infusion (Ronapreve®▼) for treating COVID-19	Black	<p>Date of NICE TA publication: 29 March 2023</p> <p>Approval for implementation: N/A</p> <p>Black statement in line with TA878, produced with input from CMDU colleagues.</p> <p>Casirivimab plus imdevimab (Ronapreve®) is not recommended for treating COVID-19.</p> <div style="text-align: center;">  <p>6.1.3_ta878_black_covid19_202305.pdf</p> </div>	<p>Supported by ICB Medicines Optimisation and Pharmacy (MOP) Group 20/6/23 and approved at ICB Finance, Investment and Resources Committee (FIRC) 27/6/23</p>


Drug and indication	RAG	Notes	ICB approval
<p>NIRMATRELVIR plus RITONAVIR tablets (Paxlovid®▼), SOTROVIMAB solution for infusion (Xevudy®▼) and TOCILIZUMAB solution for infusion (RoActemra®▼) for treating COVID-19</p>	<p>Red</p>	<p>Date of NICE TA publication: 29 March 2023</p> <p>Approval for implementation: 90 days</p> <p>Deadline for implementation: 27 June 2023</p> <p>Red statement in line with TA878, produced with input from CMDU colleagues.</p> <p>Nirmatrelvir plus ritonavir (Paxlovid®), sotrovimab (Xevudy®) and tocilizumab (RoActemra®) are recommended for treating COVID-19. ICBs will become the responsible commissioner from 27th June 2023 and community supply of COVID-19 treatments in Cheshire and Merseyside will continue to be through the CMDU.</p> <p>Costing information is currently unavailable due to significant issues in obtaining the relevant data to complete the NICE resource impact template. These issues have been escalated to NHS England by the ICB Chief Pharmacist</p> <div style="text-align: center;">  <p>6.1.2_ta878_red_covid19_202305.pdf</p> </div>	<p>Supported by ICB Medicines Optimisation and Pharmacy (MOP) Group 20/6/23 and approved at ICB Finance, Investment and Resources Committee (FIRC) 27/6/23.</p> <p>Blueteq utilisation required by ICB as agreed at FIRC.</p>

New medicines other



Drug and indication	RAG	Notes	ICB approval
<p>EPTINEZUMAB injection (Vyepti®▼) for preventing migraine</p>	<p>N/A</p>	<p>For noting.</p> <p>This prescribing statement has already been approved by NHS Cheshire and Merseyside ICB, however a query was subsequently raised in the New medicines subgroup regarding the dosage. The Summary of Product Characteristics (SPC) states that the</p>	<p>Approved at ICB MOP Group 20/6/23</p>

		<p>recommended dose is 100 mg every 12 weeks, but some patients may benefit from a dosage of 300 mg every 12 weeks.</p> <p>NICE has confirmed that the guidance in TA871 is based on the use of a 100 mg dose only, and the 300mg dose was not assessed. Therefore, wording has been added to the prescribing statement to clarify the recommended dosage in accordance with TA871.</p> <p>The legacy Cheshire and Pan Mersey formulary entries have been amended to reflect that the 300mg dose is not recommended for use.</p>	
--	--	--	--




Interface Prescribing






Drug and indication	RAG	Notes	ICB approval
Cannabis Extract oromucosal spray (Sativex®) for the treatment of moderate to severe spasticity in patients with multiple sclerosis	Amber retained	<p>Prescribing Support Information.</p> <p>Review of legacy document to create a new, harmonised Cheshire and Merseyside document. The document follows NICE NG144, which was published in November 2019. The Walton Centre confirmed all the patients who were already in the system and were awaiting this guidance are now being treated. Numbers of new patients starting treatment are expected to be very low and no significant increase in costs is expected.</p> <p> 7.1.2_Sativex_Prescribing_Support.pdf</p>	Approved at ICB MOP Group 20/6/23

Antimicrobials

Drug and indication	RAG	Notes	ICB approval
Recurrent urinary tract infection in adults	Not applicable	<p>Prescribing guideline and patient information leaflet developed from legacy guidance and based on NICE NG112.</p> <p>Includes a statement to acknowledge the current use of methenamine and a plan to address the formulary issue as part of the larger formulary harmonisation process.</p> <p>The patient information leaflet is planned for comms. review to assure readability and is provided for approval of the content.</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  8.1.2_rUTI_guide.pdf </div> <div style="text-align: center;">  8.1.5_rUTI_PIL.pdf </div> </div>	Approved at ICB MOP Group 20/6/23

APG governance documents

Drug and indication	RAG	Notes	ICB approval
CMAPG terms of reference	Not applicable	<div style="text-align: center;">  cmapg_tor_v01.pdf </div> <p>For review in three months.</p>	Approved at ICB MOP Group 20/6/23
CMAPG policy	Not applicable	<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  cmapg_policy_v01.pdf </div> <div style="text-align: center;">  organogram_202305.pdf </div> </div> <p>For review in three months, including clarification of where Trusts sit within the provider collaboratives.</p>	Approved at ICB MOP Group 20/6/23

<p>Subgroup terms of reference</p>	<p>Not applicable</p>	<p>Following a discussion at APG the following points were followed up:</p> <ul style="list-style-type: none"> • CICIP was removed from the Other NHS Trusts section as it is part of Mid Cheshire Hospitals NHS Foundation Trust. • The positioning of Alder Hey Children’s NHS Foundation in the table was considered by the subgroup Chairs, but it was decided that it should be left as it is unless Alder Hey have any objections. • Clatterbridge Cancer Centre NHS Foundation Trust will be left in the table for the time being as it is included in the APG policy and the trust is on the APG consultation mailing list. The trust will be contacted to see if they agree with this. • For review in three months, but the Interface prescribing subgroup terms of reference have an earlier review to address concerns over subgroup membership raised by LMC. <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  nmsg_tor.pdf </div> <div style="text-align: center;">  fgsg_tor.pdf </div> <div style="text-align: center;">  ipsg_tor.pdf </div> </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;"> <div style="text-align: center;">  safety_tor.pdf </div> <div style="text-align: center;">  antimicrobial_tor.pdf </div> </div>	<p>Approved at ICB MOP Group 20/6/23</p>
------------------------------------	-----------------------	--	---

APG reports

Drug and indication	Date	Notes	ICB approval
NICE TA formulary adherence	<p>April 2023</p>	<p>For noting</p>	<p>Noted at MOP Group 20/6/23</p>